Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
e brings over 27+ years of rich pharmaceutical experience
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
The emergence of new infections in India is a growing concern
Majority of organizations are looking to increase investments in public and hybrid cloud
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Subscribe To Our Newsletter & Stay Updated
